News >

Enzalutamide Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, Dec 21, 2018

Dr. Mace Rothenberg

Mace Rothenberg, MD
Enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) compared with ADT alone, according to topline results of the phase III ARCHES trial (NCT02677896).1

<.001). The OS rate at 3 years was 66% in the abiraterone acetate group versus 49% with ADT.

References

  1. Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer. Astellas Pharma Inc. Published December 20, 2018. https://prn.to/2SaGyR5?rel=0" . Accessed December 20, 2018.
  2. Hussain M, Fizazi K, Saad F, et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). J Clin Oncol. 2018;36 (suppl 6S; abstr 3).
  3. Fizazi K, Tran N, Fein LE, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x